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www.medgasres.com error 0.05, study power 80% and the proportion difference of ondansetron efficacy and placebo in other studies. Participants were excluded if had any history of cardiovascular disease, migraine headache, use of selective serotonin reuptake inhibitors (SSRIs), sensitivity to ondansetron and local anesthetics, and finally contraindication for spinal anesthesia. Inclusion criteria were including ASA I-II, 15 age of 20-35 years, patient consent, no history of cardiovascular disease (cardiac arrhythmia, ischemia and heart failure), no SSRI prescriptions, no opioid prescriptions, lack of preeclampsia and eclampsia, and no history of migraine and diabetes. [16] [17] [18] In addition, the exclusion criteria were including lack of patient participation, sensitivity to ondansetron and local anesthetics, contraindication for spinal anesthesia, repeated dural puncture, failed spinal anesthesia which requires adjuvants, and pre-pregnancy body mass index (BMI) less than 30. Verbal and written informed consent was obtained from all patients and the study protocol was approved by Ethical Committee of Arak University of Medical Sciences (approved number IR.ARAKMU.REC.1394.274), registered in the Iranian Registry of Clinical Trials with registration number ID: IRCT2016090629732N1. Subjects were assigned to three equal-sized groups using block random allocation.
Participants in the first (n = 65), second (n = 65), and control groups (n = 65) received 8 mg, 4 mg of intravenous ondansetron and normal saline, respectively, five minutes before the surgery. Chossing the dosage was according to results of other studies. 8, [19] [20] [21] Those studies showed that the ondansetron 4 mg has lower effect in prevention of PONV in compared to dexamethasone and the combining dexamethasone with ondansetron is more helpful. Therefore, ondansetron with two doses was used in this study. A final volume of 5 mL was prepared by adding normal saline, and no differences were found among them. Medications were coded and administered to three groups A, B and C by an anesthetist who was not involved in the data collection, while the patients and the resident collecting information were unaware of patient grouping.
Standard monitoring included non-invasive blood pressure, pulse oximetry and electrocardiography in all patients from admission to the operating room, throughout the surgery and to recovery period. All patients were administered 500 mL of Ringer's solution just before spinal anesthesia which was performed with a 25-gauge Quincke needle at the L 3-4 or L [4] [5] interspace, in sitting position. Patients received an intrathecal injection of 12 mg marcaine 0.5%. After the spinal anesthesia, patient is immediately placed in the supine position. With a small pillow placed under the hips, patient rotates 10° to the left to prevent the compression on the aorta and vena cava by the gravid uterus. The blood pressure and heart rate were measured before and immediately after the spinal anesthesia, while being recorded every 5-15 minutes. 12 mg of intravenous ephedrine was injected when blood pressure decreased by more than 20% of the baseline value. In case of bradycardia (below 42 beats/minute), 0.5 mg intravenous atropine was administered. The crystalloid, Ringer's solution, was administered in a volume of 10 mL per kg body weight during the surgery. Patients were excluded from the study if there was hypotension more than 20% of the baseline value which cannot be inhibited by ephedrine and atropine.
The main variable evaluated in this study was headache due to spinal anesthesia, which is a pulsating headache in the frontal or occipital areas, spreading to the neck and right shoulder. This is usually associated with photophobia, diplopia, blurred vision, dizziness, hearing loss, N/V and usually begins 24-48 hours after dural puncture, and worsens by standing up while relieves by lying down, and aggravates by head movements. Though patients with migraine were excluded, they were characterized by relief from headache due to spinal anesthesia by lying down. At 24 hours, 48 hours, 4 th day, and 7 th day, patients were asked to sit on their beds for 3 minutes and then inquire about what they feel. The patients were asked about headache severity and the complained headache due to spinal anesthesia, was graded by visual analogue scale (VAS) score as mild, 0-3; moderate, 4-6; and severe, 8-10. Moreover, the incidence of PONV was assessed in all groups as secondary outcome. 22 The following scores were assigned to scoring the severity of N/V, ranging from 0 to 3: 0 = no N/V, 1 = nausea alone, 2 = N/V, and 3 = vomiting more than twice in 30 minutes). 23 Moreover, mean blood pressure (MBP), mean heart rate (MHR) and oxygen saturation (SaO 2 ) was measured at the time of anesthesia induction, 5 
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The patients' average age was 29.53 ± 5.10 years and the mean duration of surgery was 64.03 ± 1.79 minutes. The baseline measurements conducted in three groups and the demographic variables such as age and BMI and hemodynamic characteristics was compared among three groups by analysis of variance ( Table 1) . There was no significant difference in patients of all groups regarding to age, ASA, BMI, first MAP, first heart rate, first SaO 2 and surgery duration (P ≥ 0.05). Therefore, the random allocation was good and three groups were comparable. Four patients were excluded form study due to hypotension resistant to ephedrine and atropine in three groups that showed in Figure 1 .
As shown in Table 2 , comparing the post-spinal headache in mothers undergoing C/S showed significantly higher severity of post-spinal headache in the placebo group than in the ondansetron 8 mg and 4 mg ondansetron groups at 24 hours after surgery (P < 0.010). However, no significant difference was observed between both 8 mg and 4 mg ondansetron groups based on Tukey post hoc test (P ≤ 0.05). In addition, the post-spinal headache was higher in the placebo group than in the others at 48 hours after surgery (P = 0.001). Moreover, the post-spinal headache though was lower in the 8 mg ondansetron group than in the 4 mg ondansetron group, their difference was not significant (P ≥ 0.05). At 4 days after surgery, the incidence of post-spinal headache was higher in the placebo group than the other groups (P = 0.01). Post-spinal headache in the placebo group was generally more than the other groups at all times, and their distributions were 34.92%, 35.94%, and 71.87% in the 8 mg ondansetron, 4 mg ondansetron and placebo groups, respectively. The overall incidence of the headache was generally lower in 8 mg ondansetron group (P < 0.001).
As shown in Table 3 , comparing the severity of post-spinal headache at 24, 48 hours and 4 and 7 days after surgery in the three studied groups showed that the headache severity was statistically significant among groups at 1, 4 and 7 days (P < 0.05). The most severity of post-spinal headache was generally mild, and then the severity of the headache was moderate in all groups in at different times. In addition, at all times including 24 hours, 48 hours and 4 days after surgery, lower severity of headache was observed in 8 mg ondansetron group and the highest severity was occurred in placebo group (P < 0.05).
As shown in Table 4 , PONV incidence was significantly higher in the placebo group than in the other two groups at 24 hours (P < 0.001). However, the PONV was not significant among studied groups after 48 hours (P=0.086) and 4 days (P = 0.409) after surgery. The PONV incidence was same between 8 mg and 4 mg ondansetron groups. However, the nausea incidence was higher in placebo than 8 mg and 4 mg ondansetron groups, while the nausea and/or vomiting did not occur in 8 mg ondansetron group at all studied times after C/S surgery. The most incidence of nausea and both nausea and vomiting occurred in placebo group after 24 hours, 2 and 4 days.
The analysis of variance showed that there was no significant difference in MBP among three study groups (Figure 2) at the time of anesthesia, 5 th , 10 th , 15 th , 20 th , 25 th and 30 th minutes after induction (P > 0.05) and it was almost same in all groups. Nevertheless, based on repeated measurement test, a decreasing trend was observed in MBP in all groups (P < 0.05) and this was not statistically significant between groups (P > 0.05). Based on analysis of variance no differences were found in MHR among the groups at all times (P ≥ 0.05). Moreover, the repeated measurement showed that the trend of deceasing MHR in three groups was not statistically significant (Figure 3 ). 
DiscUssiON
This study evaluated the effect of different doses of ondansetron on headache after spinal anesthesia and showed that ondansetron improved postpartum headache at 24 hours, 48 hours and 4 days after cesarean section, so that the effect of 8 mg ondansetron was more than that of 4 mg ondansetron. In general, post-spinal headache in the placebo group was higher than the other groups at all times, and its frequency distribution in ondansetron 8 mg and 4 mg ondansetron groups and placebo group was 34.92%, 35.94%, and 71.87%, respectively. Moreover, a significant difference was found in nausea, and similarly in PONV among the placebo group and other groups. Vomiting more than twice in 30 minutes was not seen in any group, while PONV was seen less in the 8 mg ondansetron group compared to the 4 mg ondansetron group. A study by Fattahi et al. 8 in 2015, aimed to explore the effect of ondansetron on postdural puncture headache in women undergoing C/S, and they stated that ondansetron can reduce the incidence of headache after spinal anesthesia and PONV, while preventing the decrease in blood pressure. This is consistent with our study on headache, nausea and vomiting. While our study uses two ondansetron doses, which both improved headaches and N/V, a single dose level of 15.0 ppm was used in the Fattahi et al.'s study. 8 In the latter study, blood pressure decreased in the ondansetron group, but no difference was found between both intervention and control groups in our study. For investigating the effects of prophylactic ondansetron on spinal anesthesia-induced hypotension, a review study by Gao et al. 24 in 2015 showed that ondansetron preventively attenuates the onset of spinal anesthesia-induced hypotension, and decrease the use of vasodilator drugs. Moreover, this reduced complications such as bradycardia and N/V. The results from this study on the effect of reducing N/V are consistent with ours. However, a newly proposed hypothesis suggests that CSFL and volume reduction result in a mechanism, i.e. compensatory intracranial vasodilation, which is responsible for post-spinal headache. 6, 10 The 5-HT3 receptors play a role in various physiological processes, comprising vasomotor reflexes, control of gastrointestinal function, pain mechanisms, cardiovascular regulation, neuronal function, and limbiccortical functioning. 10 Ondansetron is a highly selective 5-HT3 receptor antagonist commonly prescribed for prophylaxis against and treatment of PONV.
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A study compared the preventing effect of ondansetron and other drugs on PONV after spinal anesthesia for cesarean delivery and showed that same antiemetic efficacy of propofol versus ondansetron. 25 In our study, 8 mg ondansetron showed a significant effect on reducing N/V than 4 mg ondansetron. A study by Marashi et al. 26 in 2012 aimed to compare two intravenous doses of 6 and 12 mg ondansetron with placebo in suppressing post-spinal anesthesia shivering and hypotension, and found that intravenous administration of different doses of ondansetron significantly reduced spinal anesthesiainduced hypotension, bradycardia and shivering, compared to the control group, whereas no differences were found in blood pressure between our studies. The difference could be due to differences in doses of ondansetron used in both studies. The age range in the Marashi study was 20-50 years, whereas that in ours is 20-35 years. A study by Yazigi et al. 9 in 2002, which aimed to determine the effect of prophylactic ondansetron in the treatment of N/V, showed a decrease in N/V when using 8 mg ondansetron. Their results are in line with ours. However, the preventing effect of ondansetron in shivering also is demonstrated in different studies. 26, 27 We compared the 4 mg and 8 mg ondansetron against post-operative headache and nausea/vomiting after spinal anesthesia in parturient undergoing cesarean section. However, comparing the ondansetron with other drugs such as granisetron on hemodynamic changes is recommended that more extensive studies be done, exploring the complications of ondansetron in patients, the type of drug and the total dose of analgesic drugs used to alleviate headache at home. The current study is also suggested to be used in the procedures in other surgeries that the spinal anesthesia is administered.
Based on our findings, ondansetron can improve postpartum headache at 24 hours, 48 hours and 4 days after cesarean section. However, the 8 mg ondansetron was more effective than the 4-mg dose, but the difference was not significant. Moreover, the PONV was lower in 8 mg ondansetron than 4 mg ondansetron. The decreasing effect of MBP and MHR was same in all groups. 
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